Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EMR stock price vs HPQ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HPQ's multiple
Needs HPQ P/E.
Implied fair value · at EMR's multiple
Needs EMR P/E.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EMR FY 2025 (ended Sep 30, 2025) · HPQ FY 2025 (ended Oct 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
EMERSON ELECTRIC CO. · implied price per share
Bear
$40.65
Base
$47.83
Bull
$55.00
HP INC. · implied price per share
Bear
$11.43
Base
$13.45
Bull
$15.47
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.65x
-28.03x
Net debt / EBITDA
Leverage against operating earnings
2.25x
1.06x
Cash and equivalents
Liquid reserves on the balance sheet
$2.45B
$4.90B
Total debt
Interest-bearing obligations outstanding
$13.12B
$9.70B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe EMR can sustain a materially higher structural margin profile than HPQ and eventually justify a premium multiple, then holding or accumulating EMR may make sense; otherwise, the data support trimming exposure because EMR trades at far richer P/E, P/S, and EV multiples despite only similar growth.
EMR trades at a much richer valuation than HPQ despite only slightly faster revenue growth, with a 37.1x P/E versus 10.3x for HPQ and 4.7x P/S versus 0.5x. The provided implied price of $41.57 versus the current $149.82 suggests the market is pricing EMR at a substantial premium that is difficult to justify from HPQ comparison alone.
Supporting Metrics
